Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Neurocrine Biosciences, Inc.'s quarterly P/E stands at 17.2x, down 95.0% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 80.8% YoY to 17.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 33.90 | 17.24 | 23.96 | 17.20 | 29.64 | 345.63 | 34.13 | 23.23 | 54.63 | 82.10 | 22.88 | 34.30 | 24.82 |
| — | -95.0% | -29.8% | -25.9% | -45.7% | +321.0% | +49.2% | -32.3% | +120.1% | — | -32.6% | -10.9% | — | |
| P/S Ratio | 5.55 | 4.18 | 4.51 | 4.53 | 4.62 | 4.95 | 5.59 | 4.83 | 6.06 | 6.93 | 6.54 | 5.70 | 5.22 |
| — | -15.5% | -19.3% | -6.3% | -23.8% | -28.6% | -14.5% | -15.3% | +16.1% | +18.6% | -10.5% | -15.9% | -15.3% | |
| P/B Ratio | 4.99 | 4.00 | 4.47 | 4.79 | 4.71 | 4.47 | 5.42 | 4.42 | 5.70 | 5.99 | 6.04 | 5.68 | 5.10 |
| — | -10.6% | -17.6% | +8.4% | -17.3% | -25.3% | -10.2% | -22.2% | +11.8% | +2.6% | -14.3% | -16.5% | -22.1% | |
| P/FCF | 21.22 | 24.91 | 9.30 | 16.79 | 35.46 | 52.39 | 14.93 | 20.04 | 67.47 | 29.99 | 28.53 | 13.91 | 13.67 |
| — | -52.4% | -37.7% | -16.2% | -47.4% | +74.7% | -47.7% | +44.1% | +393.6% | — | +33.9% | -46.8% | -24.1% | |
| EV / EBITDA | 24.01 | 17.79 | 16.30 | 15.16 | 21.04 | 92.87 | 23.92 | 15.66 | 23.61 | 34.13 | 21.89 | 19.35 | 30.38 |
| — | -80.8% | -31.9% | -3.2% | -10.9% | +172.1% | +9.3% | -19.1% | -22.3% | — | -21.6% | -32.8% | -24.4% | |
| EV / EBIT | 25.18 | — | 15.62 | 12.81 | 22.10 | 122.26 | 20.43 | 16.13 | 24.38 | 34.20 | 17.13 | 20.10 | 19.67 |
| — | — | -23.5% | -20.5% | -9.3% | +257.5% | +19.3% | -19.8% | +24.0% | — | -32.3% | -24.6% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Neurocrine Biosciences, Inc.'s operating margin was 23.7% in Q1 2026, down 2.4 pp QoQ and up 19.6 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 25.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.2% | 98.3% | 97.8% | 98.2% | 98.4% | 98.4% | 98.5% | 98.7% | 98.4% | 98.5% | 98.4% | 97.8% | 97.5% |
| — | -0.1% | -0.7% | -0.5% | -0.1% | -0.2% | +0.2% | +1.0% | +1.0% | +0.6% | +0.2% | -0.7% | -1.3% | |
| Operating Margin | 21.6% | 23.7% | 26.2% | 30.1% | 21.2% | 4.1% | 22.6% | 29.5% | 24.6% | 19.3% | 29.2% | 28.3% | 16.3% |
| — | +476.1% | +15.7% | +1.8% | -14.0% | -78.6% | -22.5% | +4.4% | +51.5% | +170.9% | +16.2% | +25.1% | +12.4% | |
| Net Margin | 16.7% | 24.3% | 19.1% | 26.4% | 15.6% | 1.4% | 16.4% | 20.9% | 11.0% | 8.4% | 28.7% | 16.7% | 21.1% |
| — | +1661.0% | +16.2% | +26.3% | +42.0% | -83.6% | -42.7% | +25.2% | -47.8% | +146.2% | +32.7% | -5.7% | +572.1% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.4% | 5.9% | 4.9% | 7.4% | 4.1% | 0.3% | 3.9% | 5.0% | 2.7% | 1.9% | 7.0% | 4.3% | 5.4% |
| — | +1827.5% | +26.5% | +48.1% | +54.8% | -83.6% | -44.3% | +15.2% | -50.8% | +141.6% | +27.5% | -6.6% | +549.6% | |
| ROA | 11.5% | 4.1% | 3.5% | 5.1% | 2.8% | 0.2% | 2.8% | 3.8% | 1.9% | 1.3% | 4.8% | 3.0% | 3.8% |
| — | +1845.5% | +21.5% | +35.4% | +47.9% | -83.5% | -41.3% | +24.7% | -50.1% | +139.8% | +22.8% | -7.8% | +571.6% | |
| ROIC | 16.1% | 4.5% | 4.8% | 5.6% | 3.9% | 0.6% | 3.9% | 5.3% | 4.3% | 3.0% | 5.1% | 5.4% | 2.9% |
| — | +605.9% | +23.6% | +5.9% | -9.3% | -79.2% | -23.6% | -2.0% | +46.8% | +162.8% | +9.4% | +27.3% | +10.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Neurocrine Biosciences, Inc.'s Debt/EBITDA ratio is 2.1x, up from 1.9x last quarter — at a moderate level that warrants monitoring. The current ratio has weakened 6.5% YoY to 2.93x, tightening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.12 | 0.13 | 0.30 | 0.16 | 0.18 | 0.18 | 0.09 | 0.10 | 0.21 | 0.19 | 0.14 | 0.15 |
| — | -32.5% | -27.4% | +227.0% | +59.6% | -17.7% | -8.4% | -32.3% | -31.6% | +39.0% | +24.7% | -20.6% | -20.9% | |
| Debt / EBITDA | 0.64 | 2.10 | 1.90 | 3.68 | 2.87 | 14.34 | 3.05 | 1.32 | 1.68 | 4.85 | 2.75 | 1.87 | 3.51 |
| — | -85.4% | -37.7% | +178.6% | +71.2% | +195.6% | +11.1% | -29.2% | -52.2% | — | +12.6% | -35.6% | -23.4% | |
| Current Ratio | 3.39 | 2.93 | 3.39 | 3.38 | 3.20 | 3.13 | 3.40 | 4.37 | 4.19 | 2.52 | 2.45 | 2.39 | 2.57 |
| — | -6.5% | -0.1% | -22.5% | -23.6% | +24.1% | +38.4% | +83.1% | +63.1% | -34.1% | -9.2% | -4.0% | -28.0% | |
| Quick Ratio | 3.30 | 2.85 | 3.30 | 3.27 | 3.10 | 3.02 | 3.28 | 4.26 | 4.08 | 2.47 | 2.40 | 2.34 | 2.51 |
| — | -5.6% | +0.5% | -23.1% | -24.2% | +22.2% | +37.1% | +81.8% | +62.4% | -33.9% | -9.2% | -2.7% | -27.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | 2.98 | 95.73 | 181.18 | 128.36 | 93.54 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into NBIX consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NBIX stock.
Neurocrine Biosciences, Inc.'s current P/E is 33.9x. The average P/E over the last 4 quarters is 22.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Neurocrine Biosciences, Inc.'s current operating margin is 21.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Neurocrine Biosciences, Inc.'s business trajectory between earnings reports.